Hutchmed (china) Limited · HKEX:13
Hutchmed (china) — Q2 2026 Earnings Presentation
39 slides from Hutchmed (china)'s earnings presentation, Jul 30, 2026
Slide 1: Global Commercial Portfolio, Next-generation Innovative Platform
Global Commercial Portfolio Next -generation Innovative Platform July 2026 HKEX:13 | Nasdaq/AIM:HCM 1
Slide 2: Safe Harbor Statement & Disclaimer
Safe Harbor Statement & Disclaimer The performance and results of operations of the HUTCHMED Group contained within this presentation are historical in nature, and past performance is no guarantee of future results. The performance and results of operations of the Group contained within this present
Slide 3: Agenda
Agenda 1 Opening Johnny Cheng Acting Chief Executive Officer Chief Financial Officer Lorenso Chiu 2 Financial Review & Outlook Deputy Chief Financial Officer George Yuan 3 Commercial Delivery Head of Commercial (China) Guangxiu Dai 4 Pipeline Updates & ATTC Platform Head of Discovery & Global Portfo
Slide 4: H1 2026 Achievements
H1 2026 Achievements China In -market Sales Next -gen Innovation ELUNATE® & SULANDA® > 40% growth ATTC Global Study Ongoing Global Asset • 2 in Phase I – Dose Escalation FRUZAQLA® Ex -US ~ 70% growth • Another 1 IND cleared – to be in Clinic in H2 Late -Stage P ipeline Progress Key Upcoming PIII Rea
Slide 5: Financial Review & Outlook
Financial Review & Outlook Underpinned by strong financial & strategic fundamentals
Slide 6: 2026 H1 Key Financial Highlights (1/2)
2026 H1 Key Financial Highlights (1/2) In-Market Sales (US$ m) H1 2026 H1 2025 YoY Growth ELUNATE ® $61 $43 +41% SULANDA® $18 $13 +45% Financial Guidance ORPATHYS ® & Others $16 $15 +3% FRUZAQLA ® $185 $163 +14% Total In -Market Sales $280 $234 +19% Consolidated Revenue (US$ m) H1 2026 H1 2025 YoY G
Slide 7: 2026 H1 Key Financial Highlights (2/2)
2026 H1 Key Financial Highlights (2/2) R&D Expenses Net Income $79m $16m H1 2025: $72m H1 2025: $455m • Investing in in-house discovery capabilities • Continues path of profitable operations (talent & AI technology) • Prior period includes $416m SHPL divest. gain & • Multiple ATTC assets entered the
Slide 8: Commercial Delivery
Commercial Delivery Novel oncology products continue to bring growth
Slide 9: FRUZAQLA: Global Geographical Expansion
FRUZAQLA ®: Global Geographical Expansion Colon cancer is the 3rd most common cancer and 2nd leading cause of cancer -related deaths worldwide [1] In-market sales (in US$ millions) Proven global strategy Q2 YoY • H1 2026 ex-US YoY + ~70% driven by geographical expansion: +27% (CER) [2] o Recent laun
Slide 10: ELUNATE: Robust China Growth
ELUNATE® : Robust China Growth In-market sales (in US$ millions) 60.8 +41% • Expanding indications and target markets 43.0 o Successfully expanded NRDL coverage to 2L EMC (mPFS: 9.5 months) o 2L RCC (mPFS: 22.2 months) approved in May 2026 • Leading market share in 3L CRC in China H1 2025 H1 2026 10
Slide 11: ORPATHYS & SULANDA: 12% of In-market Sales
ORPATHYS® & SULANDA®: 12% of In -market Sales Positive outlook despite competitive markets with new entrants ORPATHYS® (savolitinib) SULANDA® (surufatinib) • 3L MET-amplified GC approved in June 2026 • In-market sales up 45% vs. H1 2025 • Target to include SACHI in NRDL by year end • CSCO guideline
Slide 12: Sovleplenib: Entering the New Wave of Hematology Products
Sovleplenib : Entering the New Wave of Hematology Products A novel, investigational, selective small molecule inhibitor for oral administration targeting Syk CHINA Prevalence (IQVIA) [1] China (2031e) Predictable ESLIM -01 ITP ~360,000 long -term stable Immune Thrombocytopenia disease control Expect
Slide 13: Pipeline Updates & ATTC Platform
Pipeline Updates & ATTC Platform Next-generation Antibody -Targeted Therapy Conjugate (ATTC) platform Progressing clinical development
Slide 14: H1 2026 & Recent Achievements
H1 2026 & Recent Achievements ATTC Platform Fruquintinib^ Sovleplenib Global A580 Phase I initiated China RCC NDA approved China wAIHA NDA under review & Phase III at EHA Global A830 INDs cleared (CN & US) Surufatinib China ITP NDA under review China 1L PDAC Phase III on track Savolitinib* HMPL-760
Slide 15: Savolitinib: Global & China Progress Driving Future Growth
Savolitinib Sovleplenib HMPL-760 Antibody-Targeted Therapy Conjugate (ATTC) Savolitinib: Global & China Progress Driving Future Growth Our 2nd potential global commercial asset GLOBAL SAFFRON 2L MET amplification/overexpression EGFRm NSCLC GLOBAL FIRST Enrolled 338 patients Expected Phase III Combin
Slide 16: Sovleplenib Showed High Durable Response Rate & Good Safety
Savolitinib Sovleplenib HMPL-760 Antibody-Targeted Therapy Conjugate (ATTC) Sovleplenib Showed High Durable Response Rate & Good Safety EHA ESLIM -02: wAIHA ESLIM -01: ITP 2026 (Potential NDA Approval in 2027) (Potential NDA Approval in 2027) Treated Treated Placebo Durable Response Rate [1] Placebo
Slide 17: HMPL-760: Targeting 2L DLBCL All-Comers Market
Savolitinib Sovleplenib HMPL-760 Antibody-Targeted Therapy Conjugate (ATTC) HMPL-760: Targeting 2L DLBCL All -Comers Market A highly potent, selective, and reversible inhibitor with long target engagement against BTK CHINA CHINA Phase II Completed Phase III Ongoing r/r DLBCL r/r DLBCL Diffuse large
Slide 18: HMPL-A251 Overview
Savolitinib Sovleplenib HMPL-760 Antibody -Targeted Therapy Conjugate (ATTC) HMPL-A251 Overview A first-in-class PI3K/PIKK inhibitor conjugated to a HER2 -targeted antibody Monotherapy: Market Opportunity potential to overcome DXd-mediated resistance Global Phase I Study Ongoing: HER2 expressing • P
Slide 19: HMPL-A251 Combo Therapy: Unlocking First-line Potential
Savolitinib Sovleplenib HMPL-760 Antibody -Targeted Therapy Conjugate (ATTC) HMPL-A251 Combo Therapy: Unlocking First -line Potential Combination with 1L standard of care demonstrated stronger activity and improved tolerability in pre-clinical models **: p<0.01 19
Slide 20: HMPL-A580 Overview
Savolitinib Sovleplenib HMPL-760 Antibody -Targeted Therapy Conjugate (ATTC) HMPL-A580 Overview A first-in-class PI3K/PIKK inhibitor conjugated to an EGFR -targeted antibody Monotherapy: Market Opportunity potential to overcome EGFR TKI resistance Global Phase I Study Ongoing: EGFRm NSCLC • Patients
Slide 21: HMPL-A580: The First-line Combination Strategy
Savolitinib Sovleplenib HMPL-760 Antibody -Targeted Therapy Conjugate (ATTC) HMPL-A580: The First -line Combination Strategy HMPL-A580 in combination with EGFR inhibitor demonstrated efficacy in pre -clinical models **: p<0.01 21
Slide 22: A251/A580 Payload: A Potent Inhibitor Targeting PI3K/PIKK Pathways
Savolitinib Sovleplenib HMPL-760 Antibody -Targeted Therapy Conjugate (ATTC) A251/A580 Payload : A Potent Inhibitor Targeting PI3K/PIKK Pathways Cover multiple nodes along both PI3K and PIKK pathways with high affinities Target PI3K α PI3K β/γ/δ AKT mTOR ATR ATM PAM (PI3K/AKT/mTOR) HMPL-A251/A580 pa
Slide 23: PAM Pathway: Potential to Address Huge Unmet Medical Needs
Savolitinib Sovleplenib HMPL-760 Antibody -Targeted Therapy Conjugate (ATTC) PAM Pathway: Potential to Address Huge Unmet Medical Needs PAM is the most frequently altered pathway PAM-altered frequency [6] in solid tumors 38~50% Breast Cancer Lung Cancer 30% Gastric Cancer Ovarian Cancer 9% 6% 3% ALK
Slide 24: AI-Aided Innovative Drug Discovery
AI-Aided Innovative Drug Discovery 2026 2027 2028 2029 … ATTC 1 HMPL-A251 Global P hase I ongoing (PI3K/PIKK, HER2) ATTC 2 HMPL-A580 Global P hase I ongoing (PI3K/PIKK, EGFR) ATTC 3 HMPL-A830 To initiate Global Clinical Study Candidate 4 & To initiate Global Clinical Study Candidate 5 More Early -St
Slide 25: Our Strategy
Our Strategy Revenue growth & strategic actions on path to self-sustaining
Slide 26: Outlook
Outlook • Multiple ATTCs entering clinic Innovation Accelerating • AI transformation Commercial • FRUZAQLA® – next sales milestone Near Term Progress • Hematology portfolio – commercial launch BD Interest • Engaging MNCs in multiple ATTC discussions Ongoing 26
Slide 27: Q&A Thank you!
Q&A Thank you! www.hutch -med.com 27
Slide 28: References & Abbreviations
References & Abbreviations ADS = American depositary share. FGFR = fibroblast growth factor receptor. NEC = neuroendocrine carcinoma. AIHA = autoimmune hemolytic anemia. FL = follicular lymphoma. NETs = neuroendocrine tumors. ALK = anaplastic lymphoma kinase. FPI = first patient in. NHL = Non-Hodgki
Slide 29: Appendix
Appendix
Slide 30: In-market Sales & Consolidated Revenue
In-market Sales & C onsolidated Revenue ($ in millions) In-market Sales* Consolidated Revenue** H1 2026 H1 2025 % Change (CER) H1 2026 H1 2025 % Change (CER) FRUZAQLA ® $185.4 $162.8 +14% (+14%) $43.1 $43.1 —— ELUNATE ® $60.8 $43.0 +41% (+33%) $47.1 $33.6 +40% (+32%) SULANDA ® $18.4 $12.7 +45% (+37%
Slide 31: HUTCHMED Diversified and Validated Late-stage Pipeline
HUTCHMED Diversified and Validated Late -stage Pipeline Drug Study Target Disease Status China conditional approval in Dec 2024 (2026 NRDL inclusion) FRUSICA -1 2L pMMR EMC Fruquintinib^^ China approval in May 2026 FRUSICA -2 2L RCC China approval in Jun 2025 SACHI 2L EGFRm MET-amp NSCLC China appro
Slide 32: HUTCHMED ATTC Pipeline
HUTCHMED ATTC Pipeline Drug Target Indication Status Rights ATTC 1 PI3K/PIKK, FPI in Dec 2025 Solid tumor s Global HMPL-A251 HER2 Phase I ongoing ATTC 2 PI3K/PIKK, FPI in Mar 2026 Solid tumors Global HMPL-A580 EGFR Phase I ongoing ATTC 3 To initiate global clinical study in H2 2026 Undisclosed Solid
Slide 33: SACHI: Savolitinib + TAGRISSO Phase III Registration Study in China
Savolitinib SACHI: Savolitinib + TAGRISSO® Phase III Registration Study in China • China NMPA approval in June 2025 • Demonstrated clinically meaningful improvement in OS [2] mOS : ITT mPFS : mPFS: Excl. patients who received ITT [1] Prior 3rd G EGFR -TKI [1] subsequent MET inhibitor [2] HR: 0.32 HR
Slide 34: Savolitinib: Comparison of SACHI and MARIPOSA-2
Savolitinib Savolitinib: Comparison of SACHI and MARIPOSA-2 for Patients Progressed on 3 rd Gen EGFR TKI with MET amplification MARIPOSA-2[1][2] SACHI [3] Amivantamab+chemo Savolitinib+Osimertinib Comments vs chemo vs chemo ITT: 120 vs 221 ITT: 106 vs 105 ctDNA NGS Tissue FISH Precision detection –
Slide 35: Surufatinib for 1L Pancreatic Ductal Adenocarcinoma (PDAC)
Surufatinib Surufatinib for 1L Pancreatic Ductal Adenocarcinoma ( PDAC) In combination with camrelizumab, nab -paclitaxel and gemcitabine: results from Phase II part of a randomized, open-label, active -controlled, Phase II/III study • Significantly prolonged mPFS (7.20 months vs 5.52 months) • Thou
Slide 36: Surufatinib: PDAC Demographics and Market Potential
Surufatinib Surufatinib : PDAC Demographics and Market Potential Significant unmet needs highlight growing demand for effective treatments Hard to treat Immunologically cold tumor, lacks sufficient mutations for the immune system to recognize China Market tumor-specific antigens Global Market Incide
Slide 37: HMPL-306: CR+CRh Rates in Patients with IDH1/IDH2 Mutation
HMPL-306 HMPL-306: CR+CRh Rates in Patients with IDH1 / IDH2 Mutation Phase I study [1] CR+CRh rates in patients with IDH1 mutation CR+CRh rates in patients with IDH2 mutation 150/250mg group 26.7 150/250mg group 30.0 RP2D 45.5 RP2D 50.0 150/250mg group* 33.3 150/250mg group* 35.7 RP2D* 50.0 RP2D* 6
Slide 38: HMPL-306 for IDH1/2-mutated Acute Myeloid Leukemia (AML)
HMPL-306 HMPL-306 for IDH1/2 -mutated Acute Myeloid Leukemia ( AML) Initiated RAPHAEL registrational phase III trial in May 2024 ІDH1/2 mutations ~15-25% of AML patients [3] China Market Incidence 20K [1] Nearly 25% of AML patients fail to achieve remission after treatment [4] US$100m -$200m No dual
Slide 39: Substantial sustainability delivery in 2025
Substantial sustainability delivery in 2025 Good progress on ESG targets under 5 strategic pillars, steady improvement in ESG ratings Innovation Ethics and Climate Action Human Capital Access to Healthcare Transparency Achievements: Achievements: Achievements: Achievements: Achievements: Current ESG